Crypto News

1 hour ago

Merck (MRK) Stock Climbs After FDA Greenlight for Revolutionary Cholesterol Medication

Stocks

Merck (MRK) stock gains after FDA approves Lipfendra, the first oral PCSK9 inhibitor for high cholesterol, priced competitively at $315/month.

The post Merck (MRK) Stock Climbs After FDA Greenlight for Revolutionary Cholesterol Medication appeared first on Blockonomi.

Source: Blockonomi →

Related News

Trending Category

$BHYP$M Token$S21SharesAAAAAVE tokenADAADA PriceADA exploitAIAI 2040AI AgentAI AgentsAI Data CentersAI IPOAI InvestmentAI PaymentsAI Semiconductor StocksAI SemiconductorsAI agent identity

Latest News